Stay updated with breaking news from Kronos Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Privium Fund Management UK Ltd lessened its holdings in Kronos Bio, Inc. (NASDAQ:KRON – Get Rating) by 42.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 369,402 shares of the company’s stock after selling 275,929 shares during the quarter. […]
Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML... | May 10, 2023
Kronos Bio (NASDAQ:KRON – Get Rating) will post its quarterly earnings results on Tuesday, May 2nd. Kronos Bio (NASDAQ:KRON – Get Rating) last issued its quarterly earnings data on Wednesday, March 15th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.01). On average, analysts expect […]
Kronos Bio (NASDAQ:KRON – Get Rating) will be issuing its quarterly earnings data on Tuesday, May 2nd. Kronos Bio (NASDAQ:KRON – Get Rating) last posted its earnings results on Wednesday, March 15th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.01). On average, analysts expect […]
Los Angeles, California (PRWEB) April 26, 2023 -- UCLA Technology Development Group (UCLA TDG) announced today that Albert Bourla, Chairman and CEO of Pfizer